Cyanine Dyes for G-Quadruplex DNA Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current DNA targeting drugs face challenges such as poor solubility, selectivity, toxicity, and resistance, particularly in targeting quadruplex DNA structures without binding to duplex DNA, which are crucial in cancer treatment.
Innovation Solution
Development of cyanine dyes that selectively bind to G-quadruplex DNA complexes, specifically designed to minimize aggregation and inhibit binding to duplex DNA, allowing for targeted cancer treatment by interrupting DNA replication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current DNA targeting drugs are used to target quadruplex DNA, then DNA binding activity is achieved, but poor solubility and selectivity are observed
Solution Approach 1:
The patent modifies the chemical structure of cyanine dyes by introducing specific substituents (e.g., carboxylic acid groups, sulfonate groups) and adjusting the polymethine chain length to optimize both solubility and quadruplex binding affinity. These parameter changes enable the dyes to maintain DNA binding activity while achieving sufficient solubility for in vivo administration.
2Reliability
If current DNA targeting drugs bind to DNA structures, then DNA interaction is achieved, but poor selectivity between quadruplex and duplex DNA is observed
Solution Approach 1:
The patent designs cyanine dyes with specific local structural features including planar heterocyclic rings (isoquinoline, quinoline, benzimidazole) and polymethine chains that locally interact with the G-quartet stacking surface. These localized structural qualities enable preferential binding to the unique quadruplex structure while minimizing interaction with duplex DNA.
Solution Approach 2:
The patent employs unsymmetrical cyanine structures with different heterocyclic groups or substituent patterns at each end of the polymethine chain. This asymmetry allows the dye to adopt specific orientations on the quadruplex surface that maximize binding affinity while reducing non-specific binding to duplex DNA.
3Reliability
If current DNA targeting drugs are administered, then DNA targeting is achieved, but unacceptable toxicity and resistance development occur
Solution Approach 1:
The patent optimizes the charge density and hydrophilicity parameters of the cyanine dyes by introducing ionizable groups (carboxylic acids, sulfonates) that enhance water solubility and reduce membrane permeability. These parameter changes decrease off-target effects and systemic toxicity while maintaining selective quadruplex binding in cancer cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cyanine dyes effectively bind to G-quadruplex DNA in cancer cells, minimizing toxicity and resistance, and selectively induce cell death, providing a promising approach for treating proliferative disorders like cancer.
Implementation Method 1
Cyanines which selectively bind to G-quadruplex DNA complexes
Implementation Method 2
The cyanine is preferably substituted with one or more groups that minimize or prevent aggregation of the cyanine
Implementation Method 3
telomerase inhibition
Data Source
AI summary
Cyanines which selectively bind to G-quadruplex DNA complexes, particularly quadruplexes expressed in cancer cells, and methods of making and using thereof are described herein. The cyanine can be a symmetrical or unsymmetrical streptocyanine, hemicyanine, closed chain cyanine, or combinations thereof. The cyanine is preferably substituted with one or more groups that minimize or prevent aggregation of the cyanine and/or inhibit binding of the cyanine to duplex DNA. One or more of the cyanines can be formulated with one or more pharmaceutical excipients and/or carrier to prepare pharmaceutical compositions suitable for administration to a patient, particular a human patient. The compounds and compositions described herein can be used to treat diseases or disorders characterized by the expression of G-quadruplex DNA, such as cancer.